SMS Pharmaceuticals Ltd (SMSPHARMA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by SMS Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Intimation of Investor's Conference Call
Intimation · 05 Nov 2026, 12:00 pm
SMS Pharmaceuticals Schedules Q2 and H1 FY27 Earnings Call SMS Pharmaceuticals Ltd will announce its financial results for the quarter and half-year ended 30th Sep'26 on 4th Nov'26. Following the announcement, senior management will host an earnings conference call to discuss business performance on 5th Nov'26 at 12:00 PM IST. Universal dial-in numbers include +91 22 6280 1254 and +91 22 7115 8043, alongside international toll-free lines for the US, UK, Singapore, and Hong Kong. Pre-registration via Diamond Pass is available.
Receipt of order from Income Tax Department
Others (Uncategorized) · 01 Nov 2026, 1:56 am
SMS Pharmaceuticals Secures Favorable Appellate Order Vacating ₹45.63 Crore Tax Demand SMS Pharmaceuticals Limited received an appellate order under Section 250 of the Income Tax Act, 1961, dated 30th Oct'26, from the Commissioner of Income-tax (Appeals), National Faceless Appeal Centre. The order allowed the company's appeal against the earlier assessment order dated 22nd Mar'25 for AY 2023-24 passed under Section 144 read with Section 144B. Consequently, the outstanding income tax demand of ₹45.63 crore, which included interest, stands completely vacated with no adverse financial impact on the company.
Order Received from the Income Tax Department
Others (Uncategorized) · 01 Nov 2026, 1:54 am
SMS Pharmaceuticals Receives Appellate Order Dismissing Income Tax Appeal SMS Pharmaceuticals received an appellate order on 30th Oct'26 under Section 250 of the Income Tax Act, 1961, dismissing its appeal regarding Assessment Year 2018-19. The original assessment order raised a tax demand of Rs.7.19 crore, which was subsequently reduced to Rs.40.28 lakh via a rectification order dated 28th Apr'26. The company stated that the order will not have any material impact on its financial, operational, or other activities, and it is reviewing the order to assess further legal courses of action.
Loan agreement with subsidiary of the Company
Others (Uncategorized) · 30 Oct 2026, 10:51 pm
SMS Pharmaceuticals Signs Rs 50 Crore Loan Agreement with Subsidiary SMS Peptides SMS Pharmaceuticals Limited executed a loan agreement on 30th Oct'26 to extend an unsecured loan facility of up to Rs 50 Crore in one or more tranches to its 99.99%-owned subsidiary, SMS Peptides Private Limited. The facility is intended to fund the subsidiary's business operations and constitutes an arm's-length related-party transaction with common directors. As of the disclosure date, the outstanding loan amount remains nil, and the agreement confers no special rights or equity conversion terms.
SMS Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve financial results for the ....
Intimation · 04 Nov 2026, 5:30 am
SMS Pharmaceuticals Schedules Board Meeting on 4th Nov'26 for Q2 Results SMS Pharmaceuticals Limited announced that its Board of Directors will meet on 4th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended 30th Sep'26. Additionally, the trading window for dealing in company equity shares, which has been closed for designated persons since 1st Oct'26, will remain closed through 6th Nov'26 and reopen on 7th Nov'26 in compliance with insider trading regulations.
SMS PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 04 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 04 Nov 2026, 5:30 am
Scrutinizer report
Annual General Meeting · 30 Sept 2026, 6:10 pm
SMS Pharmaceuticals Shareholders Approve All 38th AGM Resolutions SMS Pharmaceuticals Limited announced that shareholders approved all seven resolutions with requisite majority at its 38th AGM held on 29th Sep'26. Key approved ordinary resolutions include adopting FY25-26 audited financial statements, declaring dividend for FY25-26, re-appointing Dr. Sunkara Venkata Satya Shiva Prasad as Director, approving cost auditor remuneration for FY26-27, and material related-party transactions with VKT Pharma Private Limited. Additionally, special resolutions passed for the re-appointment and remuneration of Ramesh Babu Potluri as Chairman & Managing Director, alongside loan provision approval to subsidiary SMS Peptides Private Limited.
Proceedings of the Annual General Meeting of the Company
Annual General Meeting · 29 Sept 2026, 9:12 pm
Investors Group Meeting
Intimation · 10 Sept 2026, 8:45 pm
SMS Pharmaceuticals Scheduled for Emkay Global Investor Meeting on 15th Sep'26 SMS Pharmaceuticals Limited announced that its management will participate in a group analyst and institutional investor meeting at the Emkay Global Investors Meeting on 15th Sep'26 in Hyderabad. The company confirmed that discussions will focus strictly on publicly available industry and company-specific developments, with no unpublished price-sensitive information being shared.
Letter to Shareholders
Annual Report · 04 Sept 2026, 9:17 pm
BRSR for the Financial Year 2025-26
Others (Uncategorized) · 04 Sept 2026, 5:26 pm
Notice of 38th Annual General Meeting for the FY 2025-26
Annual General Meeting · 04 Sept 2026, 5:20 pm
Annual Report for the Financial Year 2025-26
Others (Uncategorized) · 04 Sept 2026, 5:07 pm
Credit Rating Intimation
Others (Uncategorized) · 02 Sept 2026, 2:25 pm
Record date for Dividend has been changed from 16th September, 2026 to 22nd September, 2026.
Dividend · 27 Aug 2026, 5:05 pm
SMS Pharma Revises AGM and Dividend Record Dates SMS Pharmaceuticals has revised its 38th Annual General Meeting (AGM) date to 29th Sep'26, previously scheduled for 23rd Sep'26. Consequently, the record date for determining dividend eligibility for FY26 has been postponed to 22nd Sep'26 from the earlier 16th Sep'26. The book closure period is now set from 23rd Sep'26 to 29th Sep'26. The changes are attributed to administrative and scheduling constraints. The dividend is subject to approval at the AGM.
Change in the date of 38th AGM of the Company from 23rd September, 2026 to 29th September, 2026.
Annual General Meeting · 27 Aug 2026, 4:49 pm
Please find the enclosure
Dividend · 06 Aug 2026, 6:29 pm
SMS Pharma Announces FY26 Dividend Record Date and Tax Details SMS Pharmaceuticals (SMSPHARMA) has recommended a final dividend of ₹0.40 per share for FY26, subject to shareholder approval at the 23 Sep'26 AGM. The record date is set for 16 Sep'26, with payment to follow after the AGM. The company has detailed the tax deduction at source (TDS) applicable, with a 10% rate for resident individuals with PAN and 20% for non-residents and residents without valid PAN. Shareholders must submit relevant tax exemption documents by 09 Sep'26 to ensure appropriate TDS.
Investor Presentation
Investor Presentation · 01 Aug 2026, 10:45 pm
SMS Pharma Q1FY27: Revenue Rises 6% YoY on High-Value API Growth SMS Pharmaceuticals reported Q1FY27 revenue from operations of ₹207 crore, up 6% YoY, driven by growth in high-value APIs. EBITDA grew 4% YoY to ₹41 crore with a stable margin of ~20%. PAT increased 8% YoY to ₹20 crore, though EPS declined 3% to ₹2.23. Gross margin remained above 45%, reflecting improved unit economics. The company's ₹280 crore capex program is on track for FY27 completion. A loan of up to ₹50 crore was approved for its subsidiary, SMS Peptides, to support its R&D facility.
Press Release on Financial Results
Press Release · 01 Aug 2026, 10:34 pm
SMS Pharma Reports Steady Q1FY27 Growth and Margin Stability SMS Pharmaceuticals posted Q1FY27 revenue of ₹207 Cr, up 6% YoY, driven by high-value APIs, with Anti-Retro Viral (ARV) sales growing 69% YoY. Gross margin expanded 217 bps YoY to 36%, reflecting improved product mix. EBITDA increased 4% YoY to ₹40.95 Cr, maintaining a stable 20% margin despite higher costs. PAT rose 8% YoY to ₹20.20 Cr with a consistent 10% margin. The company is on track with its ₹280 Cr capex program and targets 10 DMF/CEP filings for FY27.
Please find the enclosure
Others (Uncategorized) · 31 Jul 2026, 11:35 pm
SMS Pharma Q1 FY27 PAT Rises; Board Approves Subsidiary Loan and MD Re-appointment SMS Pharmaceuticals reported a consolidated Q1 FY27 Net Profit of ₹20.91 crore, up 2.0% YoY from ₹20.49 crore. Revenue from operations was ₹206.96 crore, a 5.6% YoY increase. The board approved the unaudited results for the quarter ended 30th Jun'26, re-appointed Mr. Ramesh Babu Potluri as Chairman & MD for five years from 1st Oct'26, and approved a loan up to ₹50 crore to its subsidiary, SMS Peptides Private Limited, subject to shareholder approval. The record date for the FY26 dividend is 16th Sep'26.
Fixation of Record date
Others · 31 Jul 2026, 11:05 pm
SMS Pharma Q1FY27 Results, AGM Date, and Key Board Decisions SMS Pharmaceuticals reported Q1FY27 consolidated net profit of Rs 20.9 cr, up 2% YoY, on revenue of Rs 207 cr, up 5.6% YoY. The board approved re-appointing Mr. Ramesh Babu Potluri as Chairman & MD for five years from 01st Oct'26. A loan up to Rs 50 cr to subsidiary SMS Peptides was also approved, subject to shareholder consent. The 38th AGM is scheduled for 23rd Sep'26, with the record date for any FY26 dividend set for 16th Sep'26.
Re-appointment of Director
Change in Management · 31 Jul 2026, 11:01 pm
SMS Pharma Q1'27 Results: PAT Up 8%, Board Approves Subsidiary Loan SMS Pharmaceuticals reported Q1'27 standalone results with revenue up 5.6% YoY to ₹20,696.49 lakhs and PAT increasing 16.1% YoY to ₹2,113.26 lakhs. Consolidated PAT grew 2.0% YoY to ₹2,090.90 lakhs, with an EPS of ₹2.23. The Board also approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman & MD for five years from 01st Oct'26. Additionally, the Board approved a loan of up to ₹50 crores to subsidiary SMS Peptides Private Limited, subject to shareholder approval. The AGM is set for 23rd Sep'26.
Please find the enclosure
Financial Result · 31 Jul 2026, 10:50 pm
SMS Pharma Q1'27 Results, MD Re-appointment, and Subsidiary Loan Approved SMS Pharmaceuticals reported Q1'27 standalone Net Profit of ₹21.1 Cr, up 16.1% YoY, on revenue of ₹207.0 Cr (+5.6% YoY). Consolidated Net Profit was ₹20.9 Cr, up 2.0% YoY. The Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman & MD for five years from 1st Oct'26. It also approved a loan of up to ₹50 Cr to subsidiary SMS Peptides. The 38th AGM is set for 23rd Sep'26, with 16th Sep'26 as the record date for the FY26 dividend.
Please find the enclosure
Outcome · 31 Jul 2026, 10:43 pm
SMS Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 20,696 (+5.6% YoY | -13.0% QoQ) ■ EBITDA: 4,095 (+4.0% YoY | +2.6% QoQ) ■ EBITDA Margin (%): 19.8 (-30 bps YoY | +302 bps QoQ) ■ PAT: 2,091 (+2.0% YoY | -36.1% QoQ) ■ EPS (INR): 2.23 (-3.5% YoY | -37.7% QoQ)